Affiliation:
1. From the Departments of Pediatrics,
2. Neurology,
3. Department of Pediatrics, Brown University School of Medicine, Providence, Rhode Island; and the
4. Departments of Pediatrics and Neurology, Maine Medical Center, Portland, Maine.
5. Neurosurgery,
6. Child Study Center,
7. Epidemiology and Public Health, and
8. Neurosurgery, Yale University School of Medicine, New Haven, Connecticut; the
Abstract
Background.
For preterm infants, intraventricular hemorrhage (IVH) may be associated with adverse neurodevelopmental outcome. We have demonstrated that early low-dose indomethacin treatment is associated with a decrease in both the incidence and severity of IVH in very low birth weight preterm infants. In addition, we hypothesized that the early administration of low-dose indomethacin would not be associated with an increase in the incidence of neurodevelopmental handicap at 4.5 years of age in our study children.
Methods.
To test this hypothesis, we provided neurodevelopmental follow-up for the 384 very low birth weight survivors of the Multicenter Randomized Indomethacin IVH Prevention Trial. Three hundred thirty-seven children (88%) were evaluated at 54 months' corrected age, and underwent neurodevelopmental examinations, including the Wechsler Preschool and Primary Scale of Intelligence–Revised (WPPSI-R), the Peabody Picture Vocabulary Test–Revised (PPVT-R), and standard neurologic examinations.
Results.
Of the 337 study children, 170 had been randomized to early low-dose indomethacin therapy and 167 children had received placebo. Twelve (7%) of the 165 indomethacin children and 11 (7%) of the 158 placebo children who underwent neurologic examinations were found to have cerebral palsy. For the 233 English-monolingual children for whom cognitive outcome data follow, the mean gestational age was significantly younger for the children who received indomethacin than for those who received placebo. In addition, although there were no differences in the WPPSI-R or the PPVT-R scores between the 2 groups, analysis of the WPPSI-R full-scale IQ by function range demonstrated significantly less mental retardation among those children randomized to early low-dose indomethacin (for the indomethacin study children, 9% had an IQ <70, 12% had an IQ of 70–80, and 79% had an IQ >80, compared with the placebo group, for whom 17% had an IQ <70, 18% had an IQ of 70–80, and 65% had an IQ >80). Indomethacin children also experienced significantly less difficulty with vocabulary skills as assessed by the PPVT-R when compared with placebo children.
Conclusions.
These data suggest that, for preterm neonates, the early administration of low-dose indomethacin therapy is not associated with adverse neurodevelopmental function at 54 months' corrected age.
Publisher
American Academy of Pediatrics (AAP)
Subject
Pediatrics, Perinatology and Child Health
Reference66 articles.
1. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Network, November 1989 to October 1990.;Hack;Am J Obstet Gynecol.,1995
2. Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994.;Joseph;N Engl J Med.,1998
3. Declining severity adjusted mortality: evidence of improving neonatal intensive care.;Richardson;Pediatrics.,1998
4. The behavioral and emotional well-being of school-age children with different birth weights.;McCormick;Pediatrics.,1996
5. Neonatal cranial ultrasound abnormalities in low birth weight infants: relation to cognitive outcomes at six years old.;Whitaker;Pediatrics.,1996
Cited by
115 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献